26
|
Dincer A, Mehrotra V, Aschenbrenner AJ, McCullough AA, Duchek JM, Balota DA, Chen G, Hornbeck RC, Morris JC, Benzinger TL, Gordon BA. P2-412: PRECLINICAL AD PATHOLOGY PARTIALLY MEDIATES THE RELATIONSHIP BETWEEN CORTICAL THICKNESS AND ATTENTIONAL CONTROL. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.2819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GYR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING 2019; 11:180-190. [PMID: 30847382 PMCID: PMC6389727 DOI: 10.1016/j.dadm.2018.12.008] [Citation(s) in RCA: 77] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Introduction Quantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B–based and florbetapir-based amyloid imaging in the same participants from two independent cohorts using a crossover design. Methods Pittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter-individual variability of the two tracers were compared using multivariate linear models both cross-sectionally and longitudinally. Results Global amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers. Discussion Although the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers.
Collapse
|
28
|
Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, Gordon BA, Hornbeck RC, Cash L, Ances BM, Veale T, Cash DM, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Goate A, Jack CR, Karch C, Klunk W, Koeppe RA, Marcus DS, Mayeux R, McDade E, Noble JM, Ringman J, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TL. Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2018; 10:669-677. [PMID: 30417072 PMCID: PMC6215983 DOI: 10.1016/j.dadm.2018.08.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
INTRODUCTION 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is commonly used to estimate neuronal injury in Alzheimer's disease (AD). Here, we evaluate the utility of dynamic PET measures of perfusion using 11C-Pittsburgh compound B (PiB) to estimate neuronal injury in comparison to FDG PET. METHODS FDG, early frames of PiB images, and relative PiB delivery rate constants (PiB-R1) were obtained from 110 participants from the Dominantly Inherited Alzheimer Network. Voxelwise, regional cross-sectional, and longitudinal analyses were done to evaluate the correlation between images and estimate the relationship of the imaging biomarkers with estimated time to disease progression based on family history. RESULTS Metabolism and perfusion images were spatially correlated. Regional PiB-R1 values and FDG, but not early frames of PiB images, significantly decreased in the mutation carriers with estimated year to onset and with increasing dementia severity. DISCUSSION Hypometabolism estimated by PiB-R1 may provide a measure of brain perfusion without increasing radiation exposure.
Collapse
|
29
|
Flores S, Su Y, Wang G, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Mintun MA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Bateman RJ, Benzinger TL. P3‐440: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
30
|
McCullough AA, Gordon BA, Christensen J, Dincer A, Keefe S, Flores S, Hornbeck RC, Bateman RJ, Morris JC, Ances BM, Benzinger TL. P3‐401: EXAMINING THE ABILITY OF A TAU SPATIAL SPREAD METRIC TO INDICATE DISEASE PROGRESSION COMPARED TO AN INTENSITY‐BASED APPROACH. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
McCullough AA, Gordon BA, Christensen J, Dincer A, Keefe S, Flores S, Hornbeck RC, Bateman RJ, Morris JC, Ances BM, Benzinger TL. IC‐P‐207: EXAMINING THE ABILITY OF A TAU SPATIAL SPREAD METRIC TO INDICATE DISEASE PROGRESSION COMPARED TO AN INTENSITY‐BASED APPROACH. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Flores S, Su Y, Wang G, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Mintun MA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Bateman RJ, Benzinger TL. IC‐P‐009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Benzinger TLS. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NEUROIMAGE-CLINICAL 2018; 19:406-416. [PMID: 30035025 PMCID: PMC6051499 DOI: 10.1016/j.nicl.2018.04.022] [Citation(s) in RCA: 81] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Revised: 04/17/2018] [Accepted: 04/22/2018] [Indexed: 01/18/2023]
Abstract
Amyloid imaging is a valuable tool for research and diagnosis in dementing disorders. Successful use of this tool is limited by the lack of a common standard in the quantification of amyloid imaging data. The Centiloid approach was recently proposed to address this problem and in this work, we report our implementation of this approach and evaluate the impact of differences in underlying image analysis methodologies using both cross-sectional and longitudinal datasets. The Centiloid approach successfully converts quantitative amyloid burden measurements into a common Centiloid scale (CL) and comparable dynamic range. As expected, the Centiloid values derived from different analytical approaches inherit some of the inherent benefits and drawbacks of the underlying approaches, and these differences result in statistically significant (p < 0.05) differences in the variability and group mean values. Because of these differences, even after expression in CL, the 95% specificity amyloid positivity thresholds derived from different analytic approaches varied from 5.7 CL to 11.9 CL, and the reliable worsening threshold varied from −2.0 CL to 11.0 CL. Although this difference is in part due to the dependency of the threshold determination methodology on the statistical characteristics of the measurements. When amyloid measurements obtained from different centers are combined for analysis, one should not expect Centiloid conversion to eliminate all the differences in amyloid burden measurements due to variabilities in underlying acquisition protocols and analysis techniques. The Centiloid approach brings amyloid burden measurements into a common scale. The Centiloid value inherits the characteristics of the underlying method. The Centiloid value derived from different analysis techniques remains different. The amyloid positivity thresholds in Centiloid are sensitive to implementation.
Collapse
|
34
|
Gordon BA, McCullough A, Mishra S, Blazey TM, Su Y, Christensen J, Dincer A, Jackson K, Hornbeck RC, Morris JC, Ances BM, Benzinger TL. Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2018; 10:245-252. [PMID: 29780869 PMCID: PMC5956934 DOI: 10.1016/j.dadm.2018.02.003] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
INTRODUCTION Structural magnetic resonance imaging is a marker of gray matter health and decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work has shown that both amyloid β (Aβ) and tau biomarkers are related to cortical thinning, but it is unclear what unique influences they have on the brain. METHODS Aβ pathology was measured with [18F] AV-45 (florbetapir) positron emission tomography (PET) and tau was assessed with [18F] AV-1451 (flortaucipir) PET in a population of 178 older adults, of which 123 had longitudinal magnetic resonance imaging assessments (average of 5.7 years) that preceded the PET acquisitions. RESULTS In cross-sectional analyses, greater tau PET pathology was associated with thinner cortices. When examined independently in longitudinal models, both Aβ and tau were associated with greater antecedent loss of gray matter. However, when examined in a combined model, levels of tau, but not Aβ, were still highly related to change in cortical thickness. DISCUSSION Measures of tau PET are strongly related to gray matter atrophy and likely mediate relationships between Aβ and gray matter.
Collapse
|
35
|
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 2018; 17:241-250. [PMID: 29397305 PMCID: PMC5816717 DOI: 10.1016/s1474-4422(18)30028-0] [Citation(s) in RCA: 350] [Impact Index Per Article: 58.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Revised: 11/01/2017] [Accepted: 12/15/2017] [Indexed: 12/21/2022]
Abstract
BACKGROUND Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation, hypometabolism, and structural decline that precedes the onset of clinical dementia. These pathological features evolve both temporally and spatially in the brain. In this study, we aimed to characterise where in the brain and when in the course of the disease neuroimaging biomarkers become abnormal. METHODS Between Jan 1, 2009, and Dec 31, 2015, we analysed data from mutation non-carriers, asymptomatic carriers, and symptomatic carriers from families carrying gene mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) enrolled in the Dominantly Inherited Alzheimer's Network. We analysed 11C-Pittsburgh Compound B (11C-PiB) PET, 18F-Fluorodeoxyglucose (18F-FDG) PET, and structural MRI data using regions of interest to assess change throughout the brain. We estimated rates of biomarker change as a function of estimated years to symptom onset at baseline using linear mixed-effects models and determined the earliest point at which biomarker trajectories differed between mutation carriers and non-carriers. This study is registered at ClinicalTrials.gov (number NCT00869817) FINDINGS: 11C-PiB PET was available for 346 individuals (162 with longitudinal imaging), 18F-FDG PET was available for 352 individuals (175 with longitudinal imaging), and MRI data were available for 377 individuals (201 with longitudinal imaging). We found a sequence to pathological changes, with rates of Aβ deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18·9 years [SD 3·3] before expected onset), followed by hypometabolism (14·1 years [5·1] before expected onset), and lastly structural decline (4·7 years [4·2] before expected onset). This biomarker ordering was preserved in most, but not all, regions. The temporal emergence within a biomarker varied across the brain, with the precuneus being the first cortical region for each method to show divergence between groups (22·2 years before expected onset for Aβ accumulation, 18·8 years before expected onset for hypometabolism, and 13·0 years before expected onset for cortical thinning). INTERPRETATION Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and cortical thinning compared with non-carriers which preceded the expected onset of dementia. Accrual of these pathologies varied throughout the brain, suggesting differential regional and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting as well as designing and evaluating clinical trials. FUNDING US National Institutes of Health, the German Center for Neurodegenerative Diseases, and the Medical Research Council Dementias Platform UK.
Collapse
|
36
|
Gordon BA, Blazey T, Su Y, Hari‐Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Fagan AM, Marcus DS, Jack CR, Koeppe RA, Hornbeck RC, Paumier KL, Ances BM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TL. [O1–02–03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Mishra S, Gordon BA, Blazey T, Su Y, Christensen J, Jackson K, Hornbeck RC, Morris JC, Ances BM, Benzinger TL. [P1–422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]‐AV‐1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Joseph‐Mathurin N, Kantarci K, Jack CR, Ringman JM, Salloway S, McDade E, Clifford D, Blazey T, Friedrichsen KA, Su Y, Gordon BA, Hornbeck RC, Mills S, Ances BM, Raichle ME, Marcus DS, Cairns NJ, Xiong C, Cruchaga C, Goate A, Buckles V, Paumier KL, Morris JC, Bateman RJ, Benzinger TL. [IC‐P‐057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Joseph‐Mathurin N, Kantarci K, Jack CR, Ringman JM, Salloway S, McDade E, Clifford D, Blazey T, Friedrichsen KA, Su Y, Gordon BA, Hornbeck RC, Mills S, Ances BM, Raichle ME, Marcus DS, Cairns NJ, Xiong C, Cruchaga C, Goate A, Buckles V, Paumier KL, Morris JC, Bateman RJ, Benzinger TL. [O1–02–04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Mishra S, Gordon BA, Blazey T, Su Y, Christensen J, Jackson K, Hornbeck RC, Morris JC, Ances BM, Benzinger TL. [P1–008]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]‐AV‐1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Joseph‐Mathurin N, Su Y, Blazey T, Jasielec MS, Vlassenko AG, Friedrichsen KA, Gordon BA, Hornbeck RC, Cash L, Ances BM, Raichle ME, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Fagan AM, Goate A, Jack CR, Klunk BE, Koeppe RA, Marcus DS, Mayeux R, McDade E, Paumier KL, Ringman JM, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TL. [IC‐P‐166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Mishra S, Gordon BA, Blazey T, Su Y, Christensen J, Jackson K, Hornbeck RC, Morris JC, Ances BM, Benzinger TL. [IC‐02–02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]‐AV‐1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TLS. Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 2016; 11:e0163669. [PMID: 27649320 PMCID: PMC5029931 DOI: 10.1371/journal.pone.0163669] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
44
|
Joseph-Mathurin N, Vlassenko AG, Fagan AM, Su Y, Friedrichsen KA, Owen CJ, Gordon BA, Hornbeck RC, Koeppe RA, Xiong C, Morris JC, Bateman R, Benzinger TLS. IC‐P‐117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Benzinger TL, Gordon BA, Friedrichsen KA, Su Y, Christensen J, Hornbeck RC, Mishra S, Aldea P, Cash L, Ances B, McConathy J, Koeppe RA, McDade E, Cairns NJ, Morris JC, Bateman R, Buckles V. O5‐01‐06: TAU Pet Imaging with AV‐1451 in Autosomal Dominant Alzheimer's Disease: Update from the Dominantly Inherited Alzheimer Network (DIAN). Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.709] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
46
|
Joseph-Mathurin N, Vlassenko AG, Fagan AM, Su Y, Friedrichsen KA, Owen CJ, Gordon BA, Hornbeck RC, Koeppe RA, Xiong C, Morris JC, Bateman R, Benzinger TLS. O2‐08‐05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TLS. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 2016; 11:e0152082. [PMID: 27010959 PMCID: PMC4807073 DOI: 10.1371/journal.pone.0152082] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 03/08/2016] [Indexed: 02/04/2023] Open
Abstract
Amyloid imaging plays an important role in the research and diagnosis of dementing disorders. Substantial variation in quantitative methods to measure brain amyloid burden exists in the field. The aim of this work is to investigate the impact of methodological variations to the quantification of amyloid burden using data from the Dominantly Inherited Alzheimer's Network (DIAN), an autosomal dominant Alzheimer's disease population. Cross-sectional and longitudinal [11C]-Pittsburgh Compound B (PiB) PET imaging data from the DIAN study were analyzed. Four candidate reference regions were investigated for estimation of brain amyloid burden. A regional spread function based technique was also investigated for the correction of partial volume effects. Cerebellar cortex, brain-stem, and white matter regions all had stable tracer retention during the course of disease. Partial volume correction consistently improves sensitivity to group differences and longitudinal changes over time. White matter referencing improved statistical power in the detecting longitudinal changes in relative tracer retention; however, the reason for this improvement is unclear and requires further investigation. Full dynamic acquisition and kinetic modeling improved statistical power although it may add cost and time. Several technical variations to amyloid burden quantification were examined in this study. Partial volume correction emerged as the strategy that most consistently improved statistical power for the detection of both longitudinal changes and across-group differences. For the autosomal dominant Alzheimer's disease population with PiB imaging, utilizing brainstem as a reference region with partial volume correction may be optimal for current interventional trials. Further investigation of technical issues in quantitative amyloid imaging in different study populations using different amyloid imaging tracers is warranted.
Collapse
|
48
|
Friedrichsen KA, Benzinger TL, Blazey T, Couture L, Vlassenko A, Joseph-Mathurin N, Owen CJ, Hornbeck RC, Su Y, Ances B, Morris JC. O1‐01‐06: Correlation between ASL and o‐15 water PET in the adult children study. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.07.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
49
|
Joseph-Mathurin N, Su Y, Vlassenko A, Couture L, Blazey T, Friedrichsen KA, Owen CJ, Hornbeck RC, Cash L, Stevenson TA, Ances B, Xiong C, Buckles V, Moulder KL, Morris JC, Bateman R, Raichle ME, Benzinger TL. IC‐P‐052: Comparison of cerebral glucose metabolism
18
F‐FDG, early frames of
11
C‐PIB, and cerebral blood flow
15
O‐H
2
O in autosomal dominant Alzheimer's disease. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
50
|
Joseph-Mathurin N, Su Y, Vlassenko A, Jasielec MS, Blazey T, Friedrichsen KA, Owen CJ, Hornbeck RC, Stevenson TA, Cash L, Xiong C, Ringman JM, Brickman AM, Koeppe RA, Ances B, Raichle ME, Morris JC, Bateman R, Benzinger TL. P2‐138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|